Back to Search
HOWARD HOCHSTER, M.D.
M.D.
Medical Oncology Physician
NPI: 1538160668IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
048642(CT)25MA10275600(NJ)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
25MA10275600(NJ)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
048642(CT)25MA10275600(NJ)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1980
Clinical Trials (1)
1
Linked Trials
1
Recruiting
0
With Results
Research & Publications (20)
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
PMID 19565187·Invest New Drugs·2010
3-trial
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
PMID 19581537·J Clin Oncol·2009
3-trial
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.
PMID 19221754·Cancer Chemother Pharmacol·2009
3-trial
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
PMID 19255334·J Clin Oncol·2009
3-trial
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
PMID 18640933·J Clin Oncol·2008
4-observational
The power of "p": on overpowered clinical trials and "positive" results.
PMID 19259305·Gastrointest Cancer Res·2008
8-other
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
PMID 19018087·J Clin Oncol·2008
4-observational
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.
PMID 17516069·Cancer Chemother Pharmacol·2008
3-trial
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
PMID 18830756·Ann Surg Oncol·2008
3-trial
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
PMID 18191187·Gynecol Oncol·2008
3-trial
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
PMID 18467723·J Clin Oncol·2008
3-trial
Rationale for combining biotherapy in the treatment of advanced colon cancer.
PMID 19259292·Gastrointest Cancer Res·2008
8-other
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
PMID 18361803·Clin Colorectal Cancer·2007
6-review
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.
PMID 19262703·Gastrointest Cancer Res·2007
8-other
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.
PMID 17664456·J Clin Oncol·2007
8-other
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
PMID 17876013·J Clin Oncol·2007
3-trial
Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
PMID 18048821·J Clin Oncol·2007
3-trial
Section III: Treatment of Advanced Gastrointestinal Cancers.
PMID 19330060·Gastrointest Cancer Res·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 20 YORK ST
NEW HAVEN, CT 06510 - Phone
- (203) 200-4422
Quick Facts
- NPI
- 1538160668
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 5
- Locations
- 1
- Years in Practice
- 46
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile